Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT06116565).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:55 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Exact trial NCT06116565 has a public 2025 publication with interim data. The abstract explicitly identifies this ongoing open-label Phase 2 study and concludes that dosing-interval extension showed sustained efficacy and favorable safety in atopic dermatitis, which is a clearly positive framing for this trial.

Sources
Web Searchpubmed.ncbi.nlm.nih.gov7/23/25
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis - PubMed

Abstract identifies NCT06116565 as an ongoing multicenter, open-label, single-arm trial and concludes: extending stapokibart dosing interval based on response showed sustained efficacy and favorable safety in AD.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Exact trial NCT06116565 has a public 2025 publication with interim data. The abstract explicitly identifies this ongoing open-label Phase 2 study and concludes that dosing-interval extension showed sustained efficacy and favorable safety in atopic dermatitis, which is a clearly positive framing for this trial.

Found Apr 1, 2026, 7:55 PMOutcome date Jul 23, 2025, 12:00 AMReviewed Apr 1, 2026, 7:55 PM
Web Searchpubmed.ncbi.nlm.nih.govJul 23, 2025, 12:00 AM
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis - PubMed
Abstract identifies NCT06116565 as an ongoing multicenter, open-label, single-arm trial and concludes: extending stapokibart dosing interval based on response showed sustained efficacy and favorable safety in AD.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:55 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)95% confidenceReviewed Apr 1, 2026, 7:55 PM

Exact trial NCT06116565 has a public 2025 publication with interim data. The abstract explicitly identifies this ongoing open-label Phase 2 study and concludes that dosing-interval extension showed sustained efficacy and favorable safety in atopic dermatitis, which is a clearly positive framing for this trial.